obesity and its associated consequences (1). Due to the critical role of *ARNT2* in the development of PVN, we hypothesize that hypomorphic mutations may result in early onset obesity in humans.

Methods: The Genetics of Early Childhood Obesity (GECO) study recruits children with severe obesity (BMI > 120% of 95th percentile) of early onset (< 6 years). Whole exome sequencing (WES) was performed in a subset of proband-parent trios. The functional validation of the mutation(s) in *ARNT2* is ongoing with co-transfection of tagged *Arnt2* and *Sim1* in HEK293 cells, with the induction of a luciferase reporter gene under the control of 6 repeats of bHLH-PAS core binding element by the *Arnt2-Sim1* complex.

Results: Two adolescents from unrelated families were found to have genetic variants in *ARNT2*. Subject 1 has a novel *de novo* heterozygous coding variant in *ARNT2*, c.388 C>G (p.P130A, CADD 25), predicted to be deleterious by 8/12 *in silico* algorithms. She is a 14-year old Caucasian girl with severe early onset obesity, BMI 28.1 kg/m^2 (BMIz +4.72) at 2.5 years of age that has increased to 53.54 kg/m^2 (BMIz + 3.25) at 14-years, and height > 95th %tile. She is non-dysmorphic, has developmental delay, absence seizures, behavior abnormalities & glucose intolerance/dyslipidemia secondary to obesity. Using genematcher, we identified another proband with the phenotype of obesity: an African American girl (BMIz +1.9) with biallelic inherited heterozygous variants in *ARNT2*, c.1228T>A (p.W410R, CADD 29) and c.916G>A (p.G306S, CADD 22). An only child conceived by IVF, she is non-dysmorphic and on treatment for bilateral focal epilepsy. All 3 variants are rare, with mean allele frequency < 0.005 in population-based databases such as gNOMAD. Both the patients have early onset obesity and a significant neurological phenotype. *ARNT2* is a highly constrained gene of 717 amino acids with a significant depletion of missense variants in the N-terminus (1-244 aa) and overall fewer loss of function variants in ~282,644 alleles sequenced in gNOMAD.

Conclusions: We propose that hypomorphic mutations in *ARNT2* could be a potential novel cause of monogenic obesity in humans. Future studies will investigate the molecular mechanisms causing weight dysregulation in patient specific disease relevant hypothalamic neurons.

Reference: (1) Turer et al., Dis Model Mech. 2018; 11(12)

Adipose Tissue, Appetite, and Obesity
NEURAL MECHANISMS OF OBESITY

Shared Signaling Profile Between Human MRAPα-Induced Human MC4R Constitutive Activity and Obesity-Associated Human MC4R Constitutive Activity

Rikus Botha, PhD, Shree S. Kumar, BBioMed(Hons), Natasha Grimsey, PhD, Emma I. Kay, PhD, Kathleen Grace Mountjoy, BSC,PHD
Univ of Auckland Sch of Med, Auckland, New Zealand.

SAT-598

The human melanocortin 4 receptor (hMC4R) plays a critical role in the regulation of energy balance with more than 150 distinct human obesity-associated mutations. Most exhibit defective MC4R functionality but six have been reported to associate with constitutive activity. This represents a conundrum since a lean phenotype is expected for enhanced MC4R signaling. Human melanocortin 2 receptor accessory protein alpha (hMRAPα) induces hMC4R constitutive activity in transfected HEK293 cells (1,2). We do not know whether the hMRAPα-induced gain-in-function for hMC4R would cause, or prevent, obesity because of this conundrum. Here, we hypothesize that wild-type hMC4R, obesity-associated constitutively active hMC4R and hMRAPα-induced constitutive active hMC4R can exist in distinct conformational states and elicit distinct signaling profiles. To test this, we compared transiently expressed HA-hMC4R in HEK293 cells for basal and agonist activation for adenylyl cyclase, Cre driven β-galactosidase reporter transcription, and receptor protein expression. Six previously reported obesity-associated hMC4R constitutively active variants were compared with two hMC4R constitutively active mutations not associated with obesity, two hMC4R variants associated with protection from development of obesity, five non-constitutively active hMC4R mutations associated with obesity, hMRAPα co-expressed with hMC4R, and wild-type hMC4R. Our data confirm hMC4R constitutive activity coupling to both adenylyl cyclase and Cre β-galactosidase reporter for only two hMC4R variants associated with obesity (H76R & L250Q), one hMC4R mutation (H158R) not associated with obesity, and hMRAPα co-expressed with hMC4R. We show α-MSH stimulated concentration curves for wild-type hMC4R, H76R, L250Q & H158R hMC4R variants and hMRAPα co-expressed with hMC4R coupling to adenylyl cyclase. Surprisingly, out of these, only wild-type hMC4R and H158R hMC4R variant exhibited α-MSH-stimulated Cre β-galactosidase reporter concentration curves. Western blotting and ELISA showed ~70% reduced cell surface and total receptor protein expression for hMC4R co-expressed with hMRAPα and obesity-associated constitutively active hMC4R variants, compared to wild-type hMC4R. To summarize, two constitutively active hMC4R variants (H76R and L250Q) associated with obesity, and hMC4R co-expressed with hMRAPα, share a signaling profile comprising protein expression and α-MSH stimulated functional coupling to adenylyl cyclase and Cre-reporter gene expression. We conclude (1) if hMC4R is co-expressed with hMRAPα *in vivo* it would likely contribute to human obesity, and (2) obesity-associated constitutively active hMC4R variants exhibit a signaling anomaly that may underpin development of anti-obesity therapeutics.

1. Kay EI, et al. *J Mol Endocrinol*. 2013;50:203-215.
2. Kay EI, et al. *PLoS ONE*. 2015;10(10):e0140320.

Thyroid
THYROID NEOPLASIA AND CANCER

Institutional Experience with Cytologically Indeterminate Thyroid Nodules: No Molecular Testing Versus Afirma Gene Expression Classifier or Genomic Sequencing Classifier

Preethi Polavarapu, M.B.B.S[1], Abbey Fingeret, MD[2], Ana Yuil-Valdes, MD[3], Anery Patel, MD[1], Whitney Goldner, MD[1].
[1]Division of Diabetes,Endocrinology and Metabolism, Department of Internal Medicine,University of Nebraska Medical Center, Omaha, NE, USA, [2]Division of Surgical Oncology, Department